JP6322623B2 - 乳房腫瘍の予防および処置のための酢酸ウリプリスタル - Google Patents

乳房腫瘍の予防および処置のための酢酸ウリプリスタル Download PDF

Info

Publication number
JP6322623B2
JP6322623B2 JP2015513217A JP2015513217A JP6322623B2 JP 6322623 B2 JP6322623 B2 JP 6322623B2 JP 2015513217 A JP2015513217 A JP 2015513217A JP 2015513217 A JP2015513217 A JP 2015513217A JP 6322623 B2 JP6322623 B2 JP 6322623B2
Authority
JP
Japan
Prior art keywords
cells
upa
breast
treatment
hbe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015513217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520763A (ja
JP2015520763A5 (cg-RX-API-DMAC10.html
Inventor
ミシェル・レシェ−リゴン
デルフィーヌ・レヴィ
エリン・ゲネル
アンヌ・ゴンペル
パトリシア・フォルジュ
ロディーヌ・デリュモー−コミュナル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Laboratoire HRA Pharma SAS
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Laboratoire HRA Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Laboratoire HRA Pharma SAS filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of JP2015520763A publication Critical patent/JP2015520763A/ja
Publication of JP2015520763A5 publication Critical patent/JP2015520763A5/ja
Application granted granted Critical
Publication of JP6322623B2 publication Critical patent/JP6322623B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015513217A 2012-05-25 2013-05-24 乳房腫瘍の予防および処置のための酢酸ウリプリスタル Expired - Fee Related JP6322623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305586 2012-05-25
EP12305586.5 2012-05-25
PCT/EP2013/060801 WO2013175009A1 (en) 2012-05-25 2013-05-24 Ulipristal acetate for prevention and treatment of breast tumors

Publications (3)

Publication Number Publication Date
JP2015520763A JP2015520763A (ja) 2015-07-23
JP2015520763A5 JP2015520763A5 (cg-RX-API-DMAC10.html) 2016-07-14
JP6322623B2 true JP6322623B2 (ja) 2018-05-09

Family

ID=48471021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513217A Expired - Fee Related JP6322623B2 (ja) 2012-05-25 2013-05-24 乳房腫瘍の予防および処置のための酢酸ウリプリスタル

Country Status (10)

Country Link
US (2) US20150133418A1 (cg-RX-API-DMAC10.html)
EP (1) EP2854817B1 (cg-RX-API-DMAC10.html)
JP (1) JP6322623B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150039130A (cg-RX-API-DMAC10.html)
AU (1) AU2013265163B2 (cg-RX-API-DMAC10.html)
CA (1) CA2874530A1 (cg-RX-API-DMAC10.html)
ES (1) ES2672727T3 (cg-RX-API-DMAC10.html)
HU (1) HUE037889T2 (cg-RX-API-DMAC10.html)
IL (1) IL235847B (cg-RX-API-DMAC10.html)
WO (1) WO2013175009A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102864826B1 (ko) 2023-02-07 2025-09-29 재단법인 아산사회복지재단 항암제에 대한 치료 반응성을 예측하기 위한 조성물 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5965377A (en) 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
US6514713B1 (en) 2001-07-03 2003-02-04 Hybritech Incorporated Methods of detecting BRCA1 mutations
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
AU2004217988C1 (en) 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets

Also Published As

Publication number Publication date
IL235847A0 (en) 2015-01-29
HUE037889T2 (hu) 2018-09-28
AU2013265163A1 (en) 2014-12-18
EP2854817A1 (en) 2015-04-08
IL235847B (en) 2020-03-31
ES2672727T3 (es) 2018-06-15
US20170014426A1 (en) 2017-01-19
US20150133418A1 (en) 2015-05-14
EP2854817B1 (en) 2018-03-21
JP2015520763A (ja) 2015-07-23
AU2013265163B2 (en) 2017-08-10
CA2874530A1 (en) 2013-11-28
US9814732B2 (en) 2017-11-14
KR20150039130A (ko) 2015-04-09
WO2013175009A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
Chen et al. Oestrogen‐induced epithelial–mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis
Zheng et al. ANP promotes proliferation and inhibits apoptosis of ovarian granulosa cells by NPRA/PGRMC1/EGFR complex and improves ovary functions of PCOS rats
Bello-Alvarez et al. Impact of sex in the prevalence and progression of glioblastomas: The role of gonadal steroid hormones
Bulun et al. Aromatase in aging women
Shimizu et al. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression
Yuan et al. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells
Fedotcheva Clinical use of progestins and their mechanisms of action: present and future
Communal et al. Ulipristal acetate does not impact human normal breast tissue
Small et al. The selective progesterone receptor modulator ulipristal acetate inhibits the activity of the glucocorticoid receptor
JP6425785B2 (ja) 網膜中および／または網膜下における液体貯留の処置のための方法および組成物
US9814732B2 (en) Ulipristal acetate for prevention and treatment of breast tumors
TW200900080A (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis
Panigrahy et al. Role of insulin sensitising agents in altering PSA level in PCOS
Lin et al. Maternal high-fat diet influences stroke outcome in adult rat offspring
WO2019166430A1 (en) Estriol component for use in the treatment of er-positive cancers
Perkins Investigating the mechanism of action of hormones used in hormone replacement therapy via estrogen receptor subtypes and the influence of the progesterone receptor
Hamilton et al. Manganese-induced precocious puberty alters mammary epithelial cell proliferation in female rats
US20100160275A1 (en) Methods and compositions for cancer prevention and treatment
Kloosterboer et al. Proliferation of breast cells by steroid hormones and their metabolites
Milewicz et al. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor
Gallez et al. Estetrol Combined to Progestogen for Menopause or Contraception Indication Is Neutral on Breast Cancer. Cancers 2021, 13, 2486
Wageh et al. Synthetic estrogen and progestin effects on the myogenic program following damage in C2C12 murine myoblasts
Lusis et al. Adipose Tissue Links Obesity with Breast
Aurrekoetxea Rodríguez Pharmacological inhibition of Sox2 transcription factor-mediated tamoxifen resistance in breast cancer
Ma Possible role of estrogen receptor-alpha in the signaling mechanism of progesterone receptor membrane component-1 in human breast cancer cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180409

R150 Certificate of patent or registration of utility model

Ref document number: 6322623

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees